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Towards the development of new biomaterials for use in angioplasty, star-shaped polylactic acids have 
been synthesised and shown to adhere well to living cells, by in vitro and in vivo experiments, and to 
hydrolyse over time in a physiologically relevant environment into biocompatible and bioabsorbable 
entities that are capable of bestowing properties of anticoagulation and angiogenesis to their living host. 
 
Introduction 
Cardiovascular disease, one of the leading causes for death worldwide, is often treated by stent 
implantation. However, the eﬀectiveness of this treatment is impeded by in-stent restenosis (re-
narrowing of blood vessels), which aﬀects ca. 20% of patients.
1–3
 
 
The metal skeletons of coronary stents provide mechanical stability, but have been associated 
with inflammation and thrombosis at the implanted site. To overcome this, the metal skeleton 
of stents is usually coated with biocompatible
4
 and biodegradable
5
 polymers which may 
incorporate drug molecules that inhibit thrombus and vascular smooth muscle cell (VSMC) 
proliferation. 
 
Consequent to the application of the polymeric coating, the surface of the implanted stent is often 
lipophililic but over time it becomes increasingly hydrophilic due to the increasing presence of 
polar functionalities as the molecular weight of the biodegradable polymer is reduced and also 
due to the associated crystalline-to-amorphous transition caused by the plasticising eﬀect of 
low molecular weight molecules from body fluids.
3–5
 The degree of crystallinity of the polymeric 
matrix may be further aﬀected by the plasticising eﬀect of the incorporated drug molecules.
6–8
 
The combined eﬀects of plasticisation and increasing hydrophilicity impact upon the 
therapeutically useful lifetime of the implant. Crystalline phase hydrolysis begins at the 
surface and propagates layer by layer whereas at the amorphous phase the initiation and 
propagation of chain scission is random.
5
 Since the time dependence of the degradation rate is 
key to prolonging the release of the drug from the polymer matrix, the physical blending of drug 
molecules and polymer often results in lower degrees of crystallinity, and consequently 
accelerated rates of degradation. The drug eluting stents currently in use to overcome in-stent 
restenosis are often ineﬀective due to the rapid washout of the drugs from the local delivery sites 
in the arterial wall.
9
 The use of sustained drug eluting stents carries alternative risks such as 
delayed endothelial regeneration and late thrombosis, which may cause implant rejection. Thus, 
the current impetus for the considerable research activities towards drug eluting stents is 
 provided by the need to reduce the incidence of implantation-associated thrombosis. It has been 
reported that the vessel endothelium plays an important role in preventing thrombosis and 
hyper- plasia.
7,9
 Rapid smooth muscle cell proliferation and delay of re- endothelisation have been 
found to be the pathophysiological events leading to thrombosis and in-stent restenosis. 
 
The involvement of lactide in biochemical processes renders the ring opening products of this 
monomer biocompatible and biodegradable materials for a range of biomedical applications,
4,5
 
including those that require a potent pro-angiogenic eﬀect.
10
 Further, the chain length of 
polylactic acid (PLA), may be readily controlled since the material consists of hydrolysable 
polyester functional groups and reactive carboxyl/hydroxyl chain-terminating moieties. This in 
turn aﬀords control over the hydrophilic–lipophilic balance (HLB) of the material.
11
 HLB, a 
determinant parameter of the rate of biodegradation, may be tuned through the appropriate 
design of star- or comb-shaped molecular structures that allow the interplay between the 
polyester chain length and the number of terminal functional groups,
12
  as illustrated in Fig. 1. 
 
In this work, the well-known drug dipyridamole has been used as a co-initiator with 
tin(II)ethylhexanoate (Sn(Oct)2) to eﬀect control over the degradation/hydrolysis rate of the 
resultant polymer and to enhance its capability to inhibit thrombus formation   and   
vasodilation.   The   molecular    design    is rationalised by literature observations that if 
constructed around a dipyridamole core, the resultant star-shaped PLA polymer may combine 
biocompatibility and controlled biodegradability with the therapeutic benefits (anti-
thrombogesis,
13–15
 anti-inflammation,
16,17
 and compatibility with the extra cellular matrix
18,19
) of 
the constitutional sub molecular units (Scheme 1). Thus, this paper also provides a preliminary 
assessment of star-shaped dipyridamole-cored PLA as a coating of coronary stents that may 
promote angiogenesis-facilitated re-endothelisation and prevent thrombosis and in-stent 
restenosis. 
 
 
 
  
 
Fig. 1  Eﬀect of molecular shape and structure on hydrophilicity of PLA (a < b < c < d). 
 
 
 
 
 
 
Scheme 1 Synthesis of star-shaped PLA with a dipyridamole molecular core. 
 
 
 Experimental  
Materials 
Dipyridamole, L-lactide, DL-lactide, tin(II)ethylhexanoate (Sn(Oct)2), 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), fetal bovine serum (FBS), Dulbecco's Modified Eagle's 
Medium (DMEM), Minimum Essential Medium Eagle (MEM), haemoglobin reagent, Wright's 
stain/Leishmann stain, formaldehyde, calcium chloride, D-glucose, sodium citrate and citric acid 
were obtained from Sigma Aldrich. Phosphate buﬀer saline was sourced from Hi-media. 
Chloroform, hexane, ethanol, methanol and sulfuric acid were purchased from Rankem. All 
materials were used without further purification. Toluene (Rankem) was dried over a sodium wire. 
 
 
Instrumentation 
1
H-NMR spectra (TMS, CDCl3) and 
13
C-NMR spectra (TMS, CDCl3) were obtained with a Jeol 
ECA spectrometer operating at 500 MHz and at   125 MHz   respectively.   Molecular weight 
distribution profiles were determined by GPC (30 oC; THF, 1 ml min
-1
) using a Jasco-MX2080-31 
instrument equipped with a mixed-C column and a RI detector. Polymers were injected (50 µl) into 
the  column  as  solutions  in  THF (5 mg ml
-1
); monodisperse polystyrene standards facilitated 
primary calibration. A TA-Q200 DSC instrument operating at 10 oC min
-1
 facilitated the study 
of the thermal behaviour of polymers (5 mg; aluminum pan; nitrogen atmosphere) over the range 
0–180 oC. Polymer films were deposited from solution in chloroform onto glass substrates (22 mm 
x 22 mm). Contact angle measurements (water, 10 µl; HO-IAD-CAM-01 goniometer, Image J1.36b 
software) were performed on film structures that had been allowed to dry (room temperature, 24 h) 
in a dust-free environment. 
 
 
Synthesis 
L-Lactide or DL-lactide (2 g) was introduced into a round-bottomed flask (100 ml). Dry toluene (25 
ml) was added to the vessel (constant stirring; dry nitrogen atmosphere) followed by a specified 
amount of dipyridamole (7 or 10 mg) in toluene (10 ml). Then Sn(Oct)2 (10 mg) was added 
and the temperature was allowed to increase to 100 oC. After heating for 24 h, the cooled 
reaction mixture was condensed to about half of its original volume (rotary evaporation) and 
the product was isolated by suction filtration following precipitation from ethanol/hexane (400 
ml; 20/80 v/v). The solid product was washed with methanol and dried under reduced 
pressure. 
 
 
  
Hydrolytic weight loss 
Hydrolytic weight loss experiments were conducted in vials (2 ml) containing the powdered 
sample (50 mg) and phosphate buﬀer solution (PBS; 1 ml). To simulate body temperature and 
long-term ageing, samples were maintained over specified time scales in a hot air oven at 37 o C 
and 70 oC. Weight loss was determined gravimetrically (±0.1 mg), following isolation 
(centrifugation, 5000 rpm) and drying (vacuum oven; 24 h, 70 oC) of the insoluble polymer fraction. 
Experiments were performed in triplicate and analysed using the Student's t-test. Weight loss was 
expressed as a percentage of the original weight. 
 
Separation of the hydrolysis product of star-shaped PLA 
Star-shaped PLA was hydrolysed by placing accurately weighed samples of the material (ca. 50 
mg) in phosphate buﬀered saline (PBS, 1 ml) at 70 oC for 10 days. The supernatant was separated 
by centrifugation and the extent of hydrolysis was determined as the weight loss from the dried 
solid mass that remained in the centrifugation vessel. The diluted supernatant at specified 
concentrations was used for in vitro and in vivo studies. 
 
MTT toxicity assay 
The in vitro cell toxicity of the hydrolyzed products (PBS solution) of star-shaped polymers was 
assessed by means of the MTT assay. Fibroblasts (NIH3T3; 1 x 10
4
 cells per ml) were grown 
overnight (48-well plate; 37 oC; 95% air, 5% CO2) in DMEM containing 10% fetal calf 
serum (FCS). Following removal of the medium, cells were washed with DMEM containing 
10% FCS before incubation (72 h) with specified concentrations of the hydrolysed polymer 
(0.501 mg ml
-1
, 1.02 mg ml
-1
, 2.04 mg ml
-1
, 4.08 mg ml
-1
 and 8.16 mg ml
-1
). Controls were 
provided by cell cultures that had been prepared in the absence of the hydrolysed polymer. 
Toxicity was assessed at 24 h intervals. Cells were treated with MTT in PBS (0.5 mg ml
-1
), 
incubated (CO2) for 4 h and DMSO was added to solubilise the coloured product formed as a 
result of the reduction of MTT by viable cells. The amount of coloured product formed is directly 
proportional to the number of viable cells. The plates were read at 570 nm using a Bio Rad 650 
micro plate reader. Percentage inhibition and cell viability are reported relative to those of the 
corresponding control. 
 
In vitro assessment of blood compatibility 
For the in vitro evaluation of blood compatibility of SSPLA, the hydrolysis product of PLA polymers 
(5 ml) was mixed with fresh blood (100 µl) and EDTA (5 mmol l
-1
). An aliquot (20 µl) of this mixture 
was added to hemoglobin solution (5 µl) before incubation (15 min, room temperature) and 
 subsequent evaluation by means of the cyanmethemoglobin method (HEMOCOR-D; 540 nm).  The 
changes in the platelet counts were monitored using  a Neubauer's  chamber. 
 
Platelet preparation and aggregation assay 
Blood platelets drawn from healthy volunteers were placed into an anticoagulant  solution  (0.15%  
v/v)  of  acid-citrate-dextrose (ACD: 38 mM citric acid, 75 mM Na citrate, 124 mM dextrose).
20
 
Platelet-rich plasma was isolated by centrifugation (180g;  10 min; room temperature) and then 
acidified to pH 6.5 with ACD and prostaglandin E1 (1 mM). The platelets were pelleted down by 
centrifugation (750g, 10 min, room temperature), suspended in a mixture of NaCl (130 mM), 
trisodium citrate  (10 mM), NaHCO3 (9 mM), dextrose (96 mM), MgCl2 (0.9 mM), KH2PO4 (0.81 
mM) and Tris pH 7.4 (10 mM), and then treated with CaCl2 (1.8 mM). Platelet aggregation studies 
were performed at 3, 6, 9 and 12 min using a microplate (37 oC; vigorous shaking; optical density 
measured at 405 nm). At each test concentration, samples of the hydrolysis product of SSPLLA or 
SSPDLLA in PBS (8 µl) were mixed with aliquots (90 µl) of platelets. Thrombin (0.2 units per ml) 
and heparin (4 units per ml) were used as positive and negative controls. 
 
Cell adhesion assay 
The cell adhesion assay was performed by maintaining (24 h or 48 h) the 3T3-L1-fibroblast cells in 
culture plates (MEM containing 10% FBS) that had been casted with specified PLA derivatives. A 
culture well coated with collagen served as a control. After 24 h or 48 h of incubation the culture 
medium was removed, and followed by washing with PBS, cells were fixed by first adding ethanol 
(96%, 200 µl; 30 oC; 10 min) and then crystal violet solution (0.1%, 200 µl; room temperature; 30 
min). Excess stain was removed by repeated washing steps with doubly distilled water. Crystal 
violet associated with cell nuclei was extracted by the addition of Triton-X100 (0.2%, 100 µl) and 
quantified by absorbance measurements at 570  nm.  The reported measurements  are  means  from  
three  experiments. 
 
Isolation and culture of endothelial cells from rat aorta 
Rat aorta endothelial cells (RAECs) were isolated from thoracic aortas that had been excised from 
3 week-old Sprague-Dawley rats following sacrifice of the animal. Following the removal of the 
surrounding fibro-adipose tissue (fine dissecting forceps) and after discarding the proximal and 
distal regions, aortas were cut into 1 mm ring sections and cultured (DMEM containing 10% 
FCS) in a CO2 incubator (95% air, 5% CO2; 37 
oC), according  to  the  procedure  of  Nicosia  et  
al.
21
 RAECs  were sourced from endothelial sprouts that formed from aortic rings and cultured in 
DMEM containing 10% FCS. The eﬃcacy of the hydrolysis product of SSPLLA or SSPDLLA to 
promote angio- genesis was assessed by treating these cells with specified concentrations of each 
degraded polymer. The angiogenic efficacy was evaluated by comparing (LeicaQWIN software) 
 tubular network formation [length (µm) of endothelial capillary sprouts] in ECs with those in 
untreated controls. 
 
Aortic ring assay for angiogenesis 
The aortic ring assay
22
 was carried out by exposing aortic rings maintained in DMEM containing 
10% FCS to the hydrolytic products of star-shaped PLA. To this end, aortic rings were loaded onto 
a 24 well plate (10 pieces per well) and cultured (CO2 incubator) in DMEM containing 10% FCS 
and specified concentrations of the hydrolysis product of SSPLLA or SSPDLLA. 
 
 
The eﬃcacy of angiogenesis was evaluated photomicro-graphically, by comparing the 
sprouting in aortic rings with those in controls (prepared following an identical procedure, but 
in the absence hydrolytic products of star-shaped PLA) at specified time intervals. The medium 
was replaced after 24 h. The extent of angiogenic response was quantified (area per µm
2
) by 
comparing (Leica QWIN software) the total area and the number of aortic sprouts in samples 
with those of controls.  
 
All animal experiments were performed as per the animal handling protocol conformed to the 
international standards, and was monitored by the Institutional Ethics Committee. 
 
Chorioallantoic  membrane  assay 
The chorioallantoic membrane (CAM) assay
23
 was performed using white Leghorn eggs collected 
from the poultry research station in Madhavaram, Chennai. Fertilized eggs were incubated in a 
humidified incubator (37 oC; relative humidity 80%) for four days, after which time the eggs were 
candled to identify prominent blood vessels and to assess the development of the embryo. A 
window (1 cm
2
) was cut over the CAM (small craft- grinding wheel) and test  samples were loaded 
onto a hydro-cortisone-dried filter disk and placed on the CAM at a vascular area near a previously 
identified prominent blood vessel. The window was sealed with sterile parafilm and the eggs 
placed back in the incubator. Changes in microvasculature density were assessed (digital 
imaging) after four days of incubation. 
 
Results and discussions 
1
H- and 
13
C-NMR spectroscopy 
Star-shaped PLA polymers were synthesized by a coordination intersection reaction in which the 
Sn(Oct)2-catalysed polymerization of L-lactide was initiated by the primary tetra-hydroxyl groups of 
dipyridamole to give a secondary hydroxyl group-terminated, four-armed structure. The 
1
H-NMR 
spectrum of SSPLLA is presented in Fig. 2. The stereochemistry of lactide impacted upon the 
 D 
microstructural order, which in turn influenced the crystalline order and optical activity as shown in 
Table 1.
24
 
 
13
C-NMR spectral data from Fig. 3, allowed the assessment of the Bernoullian probability of tetrad- 
and hexad-sequence distributions. The 
13
C-NMR spectra of SSPLLA and SSPDLLA with similar 
molecular weight and PDI polymers were synthesized for comparing the resonances at 69.00 and 
169.69 ppm attributing to CH and COO functionalities. SSPLLA exhibited a single chemical shift 
for CH at 69.1 ppm and COO at 169.7 ppm representing the tetrad sequence of iii, iis, sii and sis 
and the hexad sequence of iiiii, iiiis, siiii and siiis. This confirms that SSPLLA exists in a 
predominantly isotatic microstructure. On the other hand, in the case of SSPDLLA, additional 
signals for the CH group at the 69.3 ppm (isi) and 69.5 ppm (sss) tetrad sequence were seen. The 
chemical shift for the hexad sequence of the COO group at 169.15–169.45 ppm (iiisi, iisii, sisii, 
sisis, iisis and isiii) and 169.05–169.15 ppm (isisi)
25
 is consistent with the existence of atactic 
polymer chain arrangement. This was further supported by optical rotation data for SSPLLA ([α]
27
 
¼ -156o, in chloroform). The formation of optically inactive SSPDLLA is consistent with the 
random distribution of tetrad and hexad sequences in atactic microstructural arrangements. 
 
Thermal and contact angle behaviour of star-shaped PLA 
The eﬀects of tacticity on the thermal properties of star-shaped PLA polymers were studied by DSC, 
Table 2. Isotactic SSPLLA is semi-crystalline, exhibiting both Tg and melting endotherms, whereas 
heterotactic SSPDLLA is amorphous. Accordingly,
26,27
 the midpoint of the Tg range of heterotactic 
SSPDLLA was seen at a lower temperature (33 oC) than that of isotactic SSPLLA (53 oC), Fig. 4. 
The DSC data indicated that tacticity influenced the molecular arrangement. Contact angle 
measurements revealed that the order of hydrophilicity, as determined by water contact angles on 
films, was PLLA > SSPLLA > SSPDLLA; respective contact angles were measured at 80o, 68o 
and 67o (Fig. 5). The order of hydrophilicity was further reflected by the rate of hydrolysis, as 
presented in Fig. 6. Although average molecular weight may be of some significance, it is 
assumed that the main factor influencing the rate of hydrolysis is the degree of crystallinity, 
which in turn is influenced by the tacticity of each polymer.
28,29 
 
 
 
 
 
 
 D 
 
Fig. 2 
1
H-NMR spectrum of SSPLLA. H-NMR (500 MHz, CDCl3-d1, d): 1.57 (d, CH3, J ¼ 7.55 Hz), 1.65 
(s, CH2), 5.2 (q, CH, J ¼ 6.87 Hz), 4.3 (q, CH2, J ¼ 6.9 Hz), 2.1 (s, CH3), 3.7 (s, CH2). 
 
 
Table 1  Tetrad and hexad sequence proportions of SSPLLA and SSPDLLA 
 
 
Tetrad intensity (%) Hexad intensity (%) 
 
[a]
27
 
 
 
-156o 
0o 
  siiii, iiii, 
Monomer ssi sss x 10-3 isi iss x 10-3 sis, iis, sii, iii  iiiis, iiis iiisi sisii, isiii, iisii sisis, iisis 
L-Lactide — — — — 0.98  00.98 — — — 
D,L-Lactide — 0.03 0.24 0.04 0.75  21.70 13.4 19.2 27.3 
 
  
 
Fig. 3   
13
C-NMR of SSPLLA and SSPDLLA ﬁtted with Bernoullian statistical analysis of tetrad and hexad 
sequence distributions. 
 
 
 
Table 2   Molecular weight and thermal behaviour of SSPLLA and SSPDLLA 
 
 
Composition ratio Lactide (g) 
 
 
 
 
 
 
 
Fig. 4 DSC traces of SSPLLA and SSPDLLA. 
 
 
 
 
Entry no. 
 
L D,L Dipyridamole (g) Time (h) M- n(mol g
-1) PDI Tg (o C) Tc (o C) Tm  (o C) DHg (J g
-1) 
1 2 — 0.010 48 41 500 1.40 53 — 161.24 86.05 
2 — 2 0.007 48 32 000 1.35 33 — — — 
 
 Hydrolysis of star-shaped PLA 
Hydrolysis weight loss of star shaped polylactic acids with diﬀerent time periods is shown in Fig. 6. 
Weight loss of SSPLLA shows a moderate degradation rate with respect to the crystal- line 
composition and the crystalline packing of the polymer in general (PLLA (isotactic) 
crystallized in the a-form with 103 helical conformations).
30–32
 In the stereocomplex of D and 
L units, SSPDLLA (heterotactic) crystallized based on hydrogen bonding between the methyl 
and carbonyl group (CH3 O=C). Zange et al.
33 reported that the CH3 O=C hydrogen 
bonding leads to the crystallization with 31 helical conformations in the stereocomplex 
systems. At the same time, this hydrogen bonding will produce a more amount of 
amorphous phase in the polymer chain due to the physical cross linking eﬀect.
34–37
 So the 
amorphous phase of SSPDLLA is higher compared to that of SSPLLA. The DSC results in Fig. 3 
clearly indicate that the Tg of the SSPDLLA shifted towards lower temperature confirming that 
the flexibility is more than that of SSPLLA. Here, the higher amorphous phase undergoes random 
chain scission and the weight loss of the SSPDLLA is more than two folds faster than that of 
SSPLLA. The hydrolysis rate of SSPLLA follows zero order and first order with the R2 values of 0.93 
and 0.94 respectively in Fig. S2.† But, in the case of SSPDLLA, the R
2
 values were found to be 
0.78 and 0.73 respectively due to random chain scission. The molecular weight of the 
SSPDLLA was decreased from 32 000 to 17 664 in Fig. S3.† A clear shoulder was observed on 
the 4
th
 day during hydrolysis and the fragment of oligomer was found to have a molecular 
weight of less than 762 g mol
-1
. 
 
 
 
Fig. 5  Contact angle measurement of PLLA, SSPLLA and SSPDLLA in water. 
  
 
 
Fig. 6 Hydrolytic degradation proﬁles for SSPLLA and SSPDLLA in phosphate buﬀer saline (PBS) 
solution at 37 o C and 70 o C. 
 
Biocompatibility 
MTT-assays allowed a preliminary evaluation of the toxicity of the degradation products of 
SSPLLA and SSPDLLA, Fig. 7. Both degradation products (water soluble fractions with 
dipyridamole) were seen to cause a  significant increase in the proliferation of HaCaT cells 
relative to the degradation-product-free control. SSPLLA exhibited pronounced eﬀects at several 
concentrations (0.501 mg ml
-1
, 1.02 mg ml
-1
, 2.04 mg ml
-1
, 4.06 mg ml
-1
, and 8.16 mg ml
-1
). 
Consistent with the hydrolysis of the polymer to its lactic acid precursors, even at 8 mg ml
-1
, 
there was no evidence of any toxic eﬀect over 72 h. These results indicate the higher proliferative 
eﬀect of the degradation product of SSPLLA as compared with that of SSPDLLA. On the basis of 
literature reports,
38,39
 we have concluded that this may be due to the absorption and utilization of 
the L-form of lactate, which is naturally available in humans as opposed to the D and L mixture 
found in the degradation products of SSPDLLA. The results indicated that the degradation 
products of the PLA construct are biocompatible and induce cell proliferation. 
 
 
 
 
  
Fig. 8 Eﬀect of collagen, PLLA, SSPLLA, SSDPLLA on NIH 3T3-ﬁbro- blast cell adherence n ¼ 3 (24 h 
and 48 h). 
 
 
 
 
Fig. 7  MTT Assay: eﬀect of SSPLLA and SSPDLLA on cell viability and biocompatibility with 
concentrations of 0.501 mg ml
-1
, 1.02 mg ml-1, 2.04 mg ml
-1
, 4.08 mg ml
-1
  and 8.16 mg ml
-1
. 
 
 
 
 
Fig. 9   Eﬀect of control, PLLA, SSPLLA and SSPDLLA on hemocompatibility and platelet count. 
 
 
 
 Cell adherence 
The cell-adherence behaviour of the polymer was compared with the traditional implant 
materials, collagen and PLLA. The star-shaped polymers exhibited greater aﬃnity for cells as 
evaluated by the cell adhesion assay, Fig. 8. The SSPDLLA polymer shows maximum cell 
adherence that is nearly two fold that of collagen, Fig. 8. This may due to the disordered 
arrangement of polymeric chains leading to the increase in the free volume or the amorphous 
phase of the material. Crystalline or ordered arrangement of polymeric chains in SSPLLA leads to 
low free volume and limits cell adherence at the surface of polymeric crystal phases. 
Accordingly, long and linear chains of PLLA inhibit cell adherence more than star shaped 
polylactic acid samples. Since there appears to be an inverse relationship polylactic acid chains, 
and hence free volume, is a determinant factor influencing adhesion to cells. 
 
Blood compatibility of star-shaped PLA 
While hemo-compatibility values for SSPLLA and SSPDLLA polymers are comparable with 
those of the control, the hydro- sylate from PLA polymers causes a reduction in the blood- 
platelet count, Fig. 9. It is assumed that the reduction is due to the pharmacological eﬀects of the 
dipyridamole moiety as well as the bio- and hemo-compatible lactides present in the poly- mer. 
We have observed that cell adhesion is better in D,L-lactide oligomers, and that L-lactide oligomers 
exhibited superior blood compatibility. This may be due to the presence of the L-form, 
biological, lactate. To further assess the anti-platelet aggregating eﬀects of PLA polymers, the 
eﬀect of the hydrolysis products of SSPLLA and SSPDLLA on platelet aggregation was between 
the degree of crystallinity and the amount of adhered polymer, it  was  assumed  that  the  
rotational  freedom  of studied, Fig. 10: the expected, platelet anti-aggregating proper-ties were 
observed. Also, the hydrolysis products of both SSPLLA and SSPDLLA demonstrated a 
concentration-dependent inhibition of platelet aggregation that was similar to that induced by 
heparin. These results confirmed the anti-platelet aggregating properties of the constructs, 
indicating that the construct would prevent the inflammatory response that usually is associated 
with stent implantation. The prevention of initial neo-intima formation thereby reduces the 
probability of in-stent restenosis. It is assumed that the anti-platelet aggregation properties of 
PLA polymers are mainly due to the bio- and hemo-compatibility of lactide rather than that of 
dipyridamole, which is present at low concentrations. However molecular design 
considerations necessitated the incorporation of the dipyridamole core as a means of preventing 
initial platelet activation. Blood compatibility and platelet count studies demonstrated that PLA 
polymers do not elicit any platelet-aggregating eﬀects. 
 
  
Fig.  10    Eﬀect of the hydrolytic products of star-shaped polylactic acids on platelet aggregation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11 Eﬀect of SSPLLA and SSPDLLA on in vivo angiogenesis: CAM assay with the branching points of 
175 and 210. 
 
 
 
 
 
  
  
 
Fig. 12  Eﬀect of SSPLLA, SSPDLLA and control on angiogenesis: aortic ring assays. The scale bar 
represents 10 µm. 
 
 
Eﬀect of SSPLLA and SSPDLLA on angiogenesis 
CAM assay. The CAM assay demonstrated that treatment with SSPLLA or SSPDLLA causes a 
significant increase in the mean diameter and in the density of microcapillaries (Fig. 11) as 
 compared with both the positive (endothelial growth factor) and negative (endostatin) controls. The 
eﬃcacy of SSPDLLA to induce angiogenesis in CAM was greater than that of SSPLLA. This is 
attributed to the amorphous nature of SSPDLLA, compared with SSPLLA, allowing more rapid 
degradation and releasing increased levels of hydrolysed lactates. This in turn results in increased 
branching in SSPDLLA-(210 branch points) as compared with SSPLLA-(175 branch points). The 
degradation rate of SSPDLLA is faster than that of SSPLLA, with the implication that the higher  
availability  of  the  products  of  the hydrolysis promotes angiogenesis in the CAM assay. This 
is further supported by the observation that respective branch points in positive and negative 
controls were 170 and 45; vascular endothelial growth factor-treated CAM provided the positive 
control and endostatin-treated CAM was used as the negative control. The increased angiogenic 
eﬃcacy of the polymer as compared with VEGF may be due to lactide which promotes VEGF 
production and simultaneously inhibits post- translational modification; namely, the polyADP 
ribosylation of VEGF increasing biological activity.
10
 Since the more rapidly hydrolysable 
SSPDLLA exhibited the highest angiogenic eﬃcacy, it is assumed that angiogenicity is directly 
linked to the formation of lactic acid during the degradation process. The eﬀect of the hydrolysis 
product of PLLA and PDLLA on angio- genesis is presented as ESI.† The results indicated that the 
rate of the proangiogenic eﬀect is in the order: L-lactate < D,L-lactate < PDLLA < PLLA. Since 
PDLLA is more readily amenable to biochemical hydrolysis than PLLA, the former material is 
more proangiogenic. Also, the naturally available L lactate is more proangiogenic than D lactate. 
 
Aortic ring assay. The eﬀect of SSPLLA and SSPDLLA on cell types that are known to be involved in 
angiogenesis (endothelial cell, fibroblast cells and smooth muscle cells) was assessed by means of 
an established in vitro tissue explant assay, namely the aortic ring angiogenesis assay. The pro-
angiogenic eﬀects of SSPDLLA and SSPLLA on aortic rings, as indicated by the length and number 
of aortic sprouts from explants relative to those for the control, are shown in Fig. 12. Consistent 
with the CAM assay, the density of aortic ring sprouts that had formed consequent to treatment 
with SSPDLLA was higher than that induced by SSPLLA. The diﬀerence in the rate of 
angiogenesis in SSPDLLA and SSPLLA may be attributed to the physical nature that dictates the 
rate of degradation and availability of lactate in the microenvironment to promote angiogenesis. 
 
Eﬀect of SSPLLA and SDPLLA on RAEC diﬀerentiation. Consideration of the rate of 
diﬀerentiation of RAECs from a cobblestone morphology to a capillary network-like structure 
demonstrated a concentration-dependent proangiogenic eﬀect for SSPLLA and SSPDLLA as shown 
in Fig. 13. In accordance with expectations, the angiogenic eﬃcacy of SSPDLLA was greater than 
that of SSPLLA. 
 
 
 
  
Fig. 13  Eﬀect of SSPLLA, SSPDLLA and control on RAEC diﬀerentiation. The scale bar represents 10 µm. 
 
 
Conclusions 
Two star-shaped polylactic acids of diﬀering hydrophilicities have been synthesized and characterised by 
spectroscopic and analytical techniques. The tacticity of these polymers was found to determine the 
degree of crystallinity, which in turn was seen to determine hydrolytic stability. A series of in vitro and 
in vivo experiments have demonstrated that both polymers combine biocompatibility with properties of 
anti-coagulation and angiogenesis. These properties render the materials suitable candidates for use in 
coronary stents for the treatment of cardiovascular disease. 
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